{ "model": { "rank": 5944, "code": "thing-q76560", "model_id": "vr.tr.antidepressant", "name": "antidepressant", "purpose": "Enable an AI agent to recognise an antidepressant medicinal product, assess its documented condition and use constraints, and identify actions requiring clinical or pharmaceutical authority.", "family": "Thing Registry", "category": "Physical world and living systems", "status": "research-draft", "kind": "thing", "plane": "PHY", "domain": "PHY.OBJ", "industry": "", "version": "", "url": "/models/thing/q76560/", "tier": 2, "score": 63, "payload": { "layer": "wikidata", "aliases": [ "monoamine oxidase inhibitor", "Melatonin receptor agonist", "tetracyclic antidepressant", "serotonin–norepinephrine reuptake inhibitor", "selective serotonin reuptake inhibitor", "Atypical antidepressant", "noradrenergic and specific serotonergic antidepressant", "antidepressants in Japan", "second-generation antidepressive agents", "adrenergic uptake inhibitors", "tricyclic antidepressant" ], "aliasCount": 11, "merged": 11, "knownIn": 63, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": "vr.tr.antidepressant", "source": { "dataset": "wikidata", "item": "Q76560", "url": "https://www.wikidata.org/wiki/Q76560", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-07T10:14:52Z", "providers": [ "Codex", "Grok" ], "missingProviders": [], "pass": 2, "cost": { "grok": { "usd": 0.00383418, "turns": 1, "seconds": 52.5, "error": null }, "codex": { "seconds": 93.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.3\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a07b5b-a7cf-7ad1-bc8d-cd3d16d481a7\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: antidepressant\nRegistry id: vr.tr.antidepressant\nPlane / domain: PHY / PHY.OBJ\nRegistry definition: (none recorded)\nNames folded into this entry: (no" } } }, "metaModel": { "id": "THING-Q76560", "registryId": "vr.tr.antidepressant", "name": "antidepressant", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.OBJ" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q76560/", "model": { "registry_id": "vr.tr.antidepressant", "name": "antidepressant", "purpose": "Enable an AI agent to recognise an antidepressant medicinal product, assess its documented condition and use constraints, and identify actions requiring clinical or pharmaceutical authority.", "definition": "A prescription psychotropic medicine whose primary licensed indication is the treatment of depressive disorders, acting mainly by modulating monoamine neurotransmission (serotonin, noradrenaline, and/or dopamine) or related glutamatergic/melatonergic pathways.", "scope_statement": "This model owns the identity, presentation, condition and documented constraints of an antidepressant as a physical medicinal product, linking to separate models for its active substances, treatment plans and people receiving it.", "in_scope": [ "Evidence supporting classification of a medicinal product as an antidepressant", "Active ingredient composition, strength, dosage form, route and release characteristics", "Product-specific authorised uses and instructions, with jurisdiction and source dates", "Documented safety constraints relevant to evaluating a proposed use", "Condition, traceability and disposition of a particular pack or batch" ], "out_of_scope": [ "Diagnosis and longitudinal assessment of depression or other conditions", "Patient medical history, preferences and clinical risk assessment", "Individual prescribing decisions, dose schedules and treatment-change plans", "Molecular structure, synthesis and pharmacology of active substances as independent entities", "Psychotherapy delivery and organisation of mental health services" ], "distinguishing_features": [ "Require an identified medicinal product and an attributable basis for calling it an antidepressant; a mood-related marketing claim alone does not establish membership.", "Separate antidepressant product identity from the condition for which someone receives it; classification and the indication for a particular use must be recorded independently.", "Distinguish the finished medicinal product from its active substance by recording formulation, strength, route and release characteristics.", "Distinguish an antidepressant from another medicine used alongside it by requiring classification evidence for that product itself.", "Distinguish a physical product or pack from a prescription or treatment plan: instructions referring to a medicine are not the medicine." ], "characteristics": [ { "name": "Antidepressant classification basis", "kind": "category", "unit_or_values": "Source-attributed classification; confirmed, disputed or unresolved", "why_it_matters": "Establishes membership without relying on product names or the recipient's diagnosis." }, { "name": "Active ingredient composition", "kind": "relation", "unit_or_values": "Links to each identified active substance, preserving the labelled chemical form", "why_it_matters": "Supports ingredient matching and detection of overlapping products." }, { "name": "Labelled strength", "kind": "measurement", "unit_or_values": "Labelled mass per dosage unit or mass per volume, with ingredient and expression basis", "why_it_matters": "Prevents confusion between presentations and between concentration and administered dose." }, { "name": "Administration presentation", "kind": "category", "unit_or_values": "Source-attributed dosage form, administration route and release designation", "why_it_matters": "Determines which handling and administration instructions must be consulted." }, { "name": "Authorisation context", "kind": "relation", "unit_or_values": "Product authorisation record linked to jurisdiction, status and effective date", "why_it_matters": "Keeps recognised uses and restrictions tied to the applicable product and jurisdiction." }, { "name": "Applicable safety information", "kind": "relation", "unit_or_values": "Versioned product information and safety notices", "why_it_matters": "Provides an attributable basis for reviewing proposed use and escalation requirements." }, { "name": "Pack usability", "kind": "state", "unit_or_values": "Unassessed, no recorded defect, review required, quarantined or unsuitable; with evidence", "why_it_matters": "Separates observed physical suitability from clinical suitability for a person." }, { "name": "Batch and expiry identity", "kind": "category", "unit_or_values": "Manufacturer or supplier identifiers, batch identifier and labelled expiry", "why_it_matters": "Supports recall matching and assessment of whether the pack remains usable." } ], "affordances": [ "Match a label or pack to an antidepressant product record and flag uncertain identity.", "Compare ingredient, strength, route and release characteristics while identifying equivalence claims that require authoritative confirmation.", "Retrieve applicable product instructions and surface unresolved safety checks for an authorised professional.", "Link a pack to an existing prescription or treatment plan and flag mismatches without generating a new regimen.", "Record storage concerns, expiry or recall matches and route the pack for quarantine or disposition review.", "Document suspected adverse effects or treatment-change concerns and route them to the responsible clinical workflow." ] }, "sources": [ { "id": "who-atc-n06a", "title": "ATC/DDD Index 2026: N06A Antidepressants", "url": "https://www.whocc.no/atc_ddd_index/?code=N06A", "what_it_supports": "Official WHO anatomical-therapeutic classification of antidepressants as a drug class, with subgroups (N06AA non-selective monoamine reuptake inhibitors, N06AB SSRIs, N06AF MAOIs, N06AG MAO-A inhibitors, N06AX other antidepressants) and defined daily doses.", "url_status": "live" }, { "id": "nice-ng222", "title": "Depression in adults: treatment and management (NG222)", "url": "https://www.nice.org.uk/guidance/ng222", "what_it_supports": "UK clinical practice: first-line SSRI choice, stepped-care use, switching, duration of treatment, and distinction from psychological therapies and other medicines.", "url_status": "live" }, { "id": "fda-antidepressant-boxed-warning", "title": "Suicidality and Antidepressant Drugs - Boxed Warning / Medication Guide", "url": "", "what_it_supports": "US regulatory framing of the class, boxed warning on suicidality in children, adolescents and young adults, and class-wide labelling.", "url_status": "dead" }, { "id": "wikidata-q12140", "title": "antidepressant (Q12140)", "url": "https://www.wikidata.org/wiki/Q12140", "what_it_supports": "Canonical identifier for the class as a chemical/pharmacological group, with cross-links to MeSH, ATC, and related items.", "url_status": "live" } ], "structure": { "bundles": [ { "id": "antidepressant-identity", "name": "Antidepressant identity", "description": "Establishes which medicinal product is represented and why it belongs in this registry entry.", "rationale": "An agent must distinguish product classification from mood-related claims, active-substance identity and the reason a person receives treatment.", "layers": [ { "id": "classification-evidence", "name": "Classification evidence", "description": "Records the attributable basis and boundaries of antidepressant membership.", "findings": [ { "id": "membership-basis", "name": "Membership basis", "description": "Record the classification claim, its source and any disagreement without treating the registry name as proof.", "questions": [ { "text": "Which authoritative record identifies this product or its active ingredient as an antidepressant?", "kind": "provenance", "id": "membership-basis-q01" }, { "text": "How is membership distinguished from a mood-support claim or use as an accompanying medicine?", "kind": "boundary", "id": "membership-basis-q02" } ] } ] }, { "id": "product-resolution", "name": "Product resolution", "description": "Separates the medicinal product from names, substances and physical instances.", "findings": [ { "id": "identified-product", "name": "Identified product", "description": "Record enough identifying evidence to resolve the product and link a pack to it without conflating brands or formulations.", "questions": [ { "text": "Which product name, supplier, jurisdiction and product identifier resolve the medicine being represented?", "kind": "definition", "id": "identified-product-q01" }, { "text": "Does the available evidence identify a finished product, an active substance or only an unresolved name?", "kind": "boundary", "id": "identified-product-q02" } ] } ] } ] }, { "id": "composition-and-presentation", "name": "Composition and presentation", "description": "Captures the formulation distinctions needed to interpret an antidepressant pack and its instructions.", "rationale": "Ingredient names alone do not establish matching strength, administration characteristics or permissible handling.", "layers": [ { "id": "ingredient-and-strength", "name": "Ingredient and strength", "description": "Records what each dosage unit or volume contains using the label's expression basis.", "findings": [ { "id": "labelled-composition", "name": "Labelled composition", "description": "Preserve each active ingredient, its labelled form and its stated quantity rather than silently normalising potentially different expressions.", "questions": [ { "text": "Which active ingredients and chemical forms are stated in the product information?", "kind": "definition", "id": "labelled-composition-q01" }, { "text": "What strength or concentration is stated for each ingredient, in which units and on what expression basis?", "kind": "measurement", "id": "labelled-composition-q02" } ] } ] }, { "id": "release-and-administration", "name": "Release and administration", "description": "Links dosage form, route and release designation to product-specific handling instructions.", "findings": [ { "id": "presentation-constraints", "name": "Presentation constraints", "description": "Record administration characteristics and sourced permissions for altering a dosage form or comparing alternative presentations.", "questions": [ { "text": "Which dosage form, route and release designation identify this presentation?", "kind": "definition", "id": "presentation-constraints-q01" }, { "text": "What do the applicable instructions permit or prohibit regarding splitting, crushing, opening or preparing this presentation?", "kind": "action", "id": "presentation-constraints-q02" }, { "text": "What authoritative evidence is required before treating another presentation as interchangeable?", "kind": "boundary", "id": "presentation-constraints-q03" } ] } ] } ] }, { "id": "therapeutic-use-context", "name": "Therapeutic use context", "description": "Connects the antidepressant product to documented uses and an externally governed treatment plan.", "rationale": "Product classification, authorised indications and the purpose of an individual prescription are distinct facts.", "layers": [ { "id": "authorised-use", "name": "Authorised use", "description": "Records the jurisdiction-specific scope of the product's authorisation.", "findings": [ { "id": "indication-and-population-boundaries", "name": "Indication and population boundaries", "description": "Represent labelled indications and population limits as dated source claims rather than universal permissions.", "questions": [ { "text": "Which indications and population boundaries appear in the applicable product authorisation?", "kind": "boundary", "id": "indication-and-population-boundaries-q01" }, { "text": "Which jurisdiction, document version and effective date support those boundaries?", "kind": "provenance", "id": "indication-and-population-boundaries-q02" } ] } ] }, { "id": "treatment-plan-link", "name": "Treatment plan link", "description": "Relates the product to an existing clinical instruction without owning prescribing decisions.", "findings": [ { "id": "intended-use-match", "name": "Intended use match", "description": "Record whether the identified presentation matches the referenced prescription and keep the clinical purpose in the linked treatment plan.", "questions": [ { "text": "Which authorised prescription or treatment-plan record specifies the intended product and presentation?", "kind": "provenance", "id": "intended-use-match-q01" }, { "text": "Which identity, strength, route or release mismatches require resolution before the proposed action proceeds?", "kind": "action", "id": "intended-use-match-q02" } ] } ] } ] }, { "id": "safety-and-treatment-changes", "name": "Safety and treatment changes", "description": "Makes antidepressant safety information and treatment-transition constraints available for professional review.", "rationale": "An agent needs to recognise unresolved contraindication, interaction, monitoring and treatment-change questions without deciding a person's regimen.", "layers": [ { "id": "use-safety-review", "name": "Use safety review", "description": "Links product-specific warnings to the external information required to assess a proposed use.", "findings": [ { "id": "safety-check-requirements", "name": "Safety check requirements", "description": "Record sourced contraindications, interactions and monitoring requirements, keeping unknown patient context distinct from a completed check.", "questions": [ { "text": "Which contraindications, interacting substances and monitoring requirements are stated for this antidepressant product?", "kind": "provenance", "id": "safety-check-requirements-q01" }, { "text": "Which checks require linked information about other medicines, age, pregnancy or relevant organ function?", "kind": "boundary", "id": "safety-check-requirements-q02" }, { "text": "What sourced escalation instructions apply to reported worsening mood, suicidal thoughts or other serious suspected reactions?", "kind": "action", "id": "safety-check-requirements-q03" } ] } ] }, { "id": "initiation-switching-and-stopping", "name": "Initiation, switching and stopping", "description": "Records where starting, changing or ending treatment requires an explicit clinical plan.", "findings": [ { "id": "transition-instructions", "name": "Transition instructions", "description": "Link product-specific information about treatment transitions to the responsible clinician's plan and preserve unresolved symptom attribution.", "questions": [ { "text": "Which sourced instructions address initiation, missed doses, switching, interruption or discontinuation for this product?", "kind": "provenance", "id": "transition-instructions-q01" }, { "text": "Which proposed changes require a documented clinician decision before an agent may support their execution?", "kind": "action", "id": "transition-instructions-q02" }, { "text": "How will possible discontinuation effects, adverse effects and recurrence of the treated condition be recorded without asserting an unassessed cause?", "kind": "boundary", "id": "transition-instructions-q03" } ] } ] } ] }, { "id": "pack-condition-and-disposition", "name": "Pack condition and disposition", "description": "Assesses a physical antidepressant pack against its specific formulation and supply requirements.", "rationale": "A correctly identified antidepressant may still require withholding from use because its provenance, condition or applicable instructions are unresolved.", "layers": [ { "id": "traceability-and-condition", "name": "Traceability and condition", "description": "Connects pack evidence to product-specific expiry, storage and recall information.", "findings": [ { "id": "pack-usability-evidence", "name": "Pack usability evidence", "description": "Record batch identity, expiry, observed damage and storage evidence, including any applicable limit after opening or preparation.", "questions": [ { "text": "Which product and batch identifiers connect this pack to supply records and applicable recall notices?", "kind": "provenance", "id": "pack-usability-evidence-q01" }, { "text": "What evidence supports compliance with this presentation's expiry, storage and any after-opening or preparation limits?", "kind": "measurement", "id": "pack-usability-evidence-q02" } ] } ] }, { "id": "permitted-pack-actions", "name": "Permitted pack actions", "description": "Bounds physical handling and disposition using product information and applicable local authority.", "findings": [ { "id": "handling-and-disposition-decision", "name": "Handling and disposition decision", "description": "Record the evidence and authority supporting supply, administration support, quarantine, return or disposal of the identified pack.", "questions": [ { "text": "Which applicable supply rules and professional instructions govern dispensing or administration of this antidepressant?", "kind": "action", "id": "handling-and-disposition-decision-q01" }, { "text": "Which observed defects, recall matches or unresolved identity concerns require quarantine or professional review?", "kind": "action", "id": "handling-and-disposition-decision-q02" }, { "text": "Which local instructions govern return or disposal of unused quantities of this product?", "kind": "provenance", "id": "handling-and-disposition-decision-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Selective serotonin reuptake inhibitors (SSRIs)", "Serotonin-noradrenaline reuptake inhibitors (SNRIs)", "Tricyclic antidepressants (TCAs)", "Monoamine oxidase inhibitors (MAOIs)", "Atypical / multimodal antidepressants (e.g. mirtazapine, bupropion, vortioxetine)", "NMDA-receptor modulators used as antidepressants (e.g. esketamine, ketamine)", "Melatonergic antidepressants (agomelatine)", "Herbal products used as antidepressants (St John's wort / Hypericum)" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of antidepressant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "scheme": "Wikidata", "value_or_pattern": "Q12140", "note": "Item for the pharmacological class 'antidepressant'" }, { "scheme": "WHO ATC", "value_or_pattern": "N06A*", "note": "Nervous system → psychoanaleptics → antidepressants; subgroups N06AA, N06AB, N06AF, N06AG, N06AX" }, { "scheme": "MeSH", "value_or_pattern": "D000928", "note": "Descriptor 'Antidepressive Agents'" }, { "scheme": "RxNorm", "value_or_pattern": "TTY=IN or SCD under antidepressant class", "note": "US ingredient and clinical-drug codes for individual agents, not the class as a whole" } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of antidepressant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "WHO Collaborating Centre for Drug Statistics Methodology - ATC/DDD classification N06A", "US FDA - class labelling and boxed warning on suicidality (21 CFR drug labelling; Medication Guides)", "EMA / national competent authorities - marketing authorisation, SmPC, and pharmacovigilance for individual products", "NICE (England & Wales) - NG222 Depression in adults", "Controlled-substance scheduling is generally not class-wide (most oral antidepressants are prescription-only, not scheduled; ketamine/esketamine are exceptions)" ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of antidepressant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Primary-care and psychiatric outpatient prescribing for major depressive disorder, often after or alongside psychological therapy", "Licensed or off-label use for anxiety disorders, OCD, PTSD, neuropathic pain (e.g. duloxetine, amitriptyline), migraine prophylaxis, and smoking cessation (bupropion)", "Hospital and crisis use of rapid-acting agents (IV ketamine, intranasal esketamine) for treatment-resistant depression", "Dispensed as oral tablets/capsules for weeks to years; treatment is typically continued 6-12 months after remission of a first episode" ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of antidepressant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "quantity": "Defined Daily Dose (WHO DDD)", "typical_range": "agent-specific (e.g. sertraline 50, fluoxetine 20, amitriptyline 75, venlafaxine 100)", "unit": "mg/day" }, { "quantity": "Therapeutic plasma concentration (TDM, selected agents)", "typical_range": "e.g. nortriptyline ~50-150; amitriptyline+nortriptyline ~80-200; venlafaxine+ODV ~100-400", "unit": "ng/mL" }, { "quantity": "Time to clinical response", "typical_range": "2-6 weeks for conventional monoaminergic agents; hours to days for ketamine/esketamine", "unit": "weeks (or hours for NMDA agents)" }, { "quantity": "Treatment duration after first-episode remission", "typical_range": "6-12", "unit": "months" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of antidepressant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Inadequate response or treatment-resistant depression despite adequate dose and duration", "Antidepressant discontinuation / withdrawal syndrome after abrupt stop or missed doses (especially short-half-life SNRIs/SSRIs)", "Increased suicidal thinking and behaviour in people under 25, particularly early in treatment", "Serotonin syndrome when combined with other serotonergic drugs (MAOIs, triptans, tramadol, St John's wort)", "Hyponatraemia (SSRIs/SNRIs, especially in older adults), QTc prolongation (citalopram, some TCAs), seizures and overdose lethality (TCAs, MAOIs)", "Manic switch in undiagnosed bipolar disorder", "Sexual dysfunction, weight gain, bleeding risk with SSRIs (platelet serotonin)" ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of antidepressant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "First-line agent choice differs: SSRIs dominate in UK/US/EU; some East Asian practice still uses more TCAs or locally marketed agents (e.g. tianeptine in parts of Europe/Asia, restricted in others)", "St John's wort is a registered herbal medicine in Germany and some EU states, a dietary supplement in the US, and not a licensed antidepressant in the UK NHS pathway", "Esketamine (Spravato) availability and reimbursement vary widely; IV ketamine for depression is often off-label outside specialist clinics", "Direct-to-consumer advertising of named antidepressants is permitted in the US and New Zealand, not in most other countries" ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of antidepressant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "name": "Anxiolytic / benzodiazepine", "difference": "Benzodiazepines act on GABA-A and are used for acute anxiety/insomnia; they are not antidepressants. An antidepressant may treat anxiety over weeks but does not produce immediate GABA-ergic sedation." }, { "name": "Mood stabiliser (lithium, valproate, lamotrigine)", "difference": "Mood stabilisers are licensed primarily for bipolar disorder; antidepressants treat unipolar depression and can precipitate mania if bipolar illness is missed." }, { "name": "Antipsychotic", "difference": "Antipsychotics target dopamine D2 (and often 5-HT2A); some (quetiapine, aripiprazole) are adjuncts in depression but the class indication is psychosis/mania, not first-line unipolar depression." }, { "name": "Stimulant / wakefulness agent", "difference": "Stimulants increase catecholamines for ADHD/narcolepsy and are not licensed as antidepressants, though they may lift energy; they lack the delayed monoamine-reuptake therapeutic profile of standard antidepressants." }, { "name": "Psychotherapy / neurostimulation (CBT, ECT, rTMS)", "difference": "These are interventions, not drugs; they may be first-line or alternatives and are not classified under ATC N06A." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of antidepressant this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does an existing world model already own antidepressant medicinal products or a sufficiently complete parent concept, requiring a link instead of a separate publication?", "Does the registry intend this entry to cover active substances as well as finished medicinal products, and how should the PHY.OBJ boundary be resolved?", "Which classification authorities should establish membership, especially for combination products, disputed classifications and products authorised differently across jurisdictions?", "Which primary product records and safety sources will be researched, versioned and maintained before this structural draft can become a supported publication?", "Where should responsibility sit between this model and neighbouring clinical models for monitoring, treatment transitions and assessment of reported symptoms?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 32 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "device, machine or tool", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a antidepressant, record what state it is in, and decide what may be done with it.", "whatItIs": "Enable an AI agent to recognise an antidepressant medicinal product, assess its documented condition and use constraints, and identify actions requiring clinical or pharmaceutical authority.", "characteristics": { "substance": "material", "origin": "manufactured", "agency": "inert", "mobility": "varies" }, "whatYouCanDoWithIt": [ "observed and measured" ], "distinguishingFeatures": [ "Names folded into this entry, which a task may need to split apart again: monoamine oxidase inhibitor, Melatonin receptor agonist, tetracyclic antidepressant, serotonin–norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, Atypical antidepressant, noradrenergic and specific serotonergic antidepressant, antidepressants in Japan, second-generation antidepressive agents, adrenergic uptake inhibitors, tricyclic antidepressant.", "11 finer distinctions are held as aliases rather than separate entries, because telling them apart needs a task that asks for it.", "Described in 63 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a antidepressant, and on what evidence are they told apart?" ], "whatItIsMadeOf": "matter you can touch", "physicalCharacter": [ "Mobility varies between examples.", "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "observe it, measure it, record its state" ], "howItIsRecognised": [ "Recognised by form, by the arrangement of its controls, and by markings - a plate, a model number, a certification mark. Form alone rarely separates two models that do very different things." ], "relatedModels": [ { "relation": "covers", "note": "Finer kinds folded into this entry because telling them apart needs a task that asks for it. Each is a model waiting to be split out when one does.", "targets": [ "monoamine oxidase inhibitor", "Melatonin receptor agonist", "tetracyclic antidepressant", "serotonin–norepinephrine reuptake inhibitor", "selective serotonin reuptake inhibitor", "Atypical antidepressant", "noradrenergic and specific serotonergic antidepressant", "antidepressants in Japan", "second-generation antidepressive agents", "adrenergic uptake inhibitors", "tricyclic antidepressant" ] } ], "standing": "Described in 63 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is. 11 finer distinctions are held inside this entry as names rather than as separate models.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one antidepressant from another, and a antidepressant from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a antidepressant sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a antidepressant from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "form-and-composition", "name": "Form, composition and condition", "description": "What a antidepressant is made of, what shape and size it takes, and what state it is in.", "rationale": "A physical thing can be measured, and a model that cannot record its measurements cannot support any decision that depends on them.", "layers": [ { "id": "form-and-dimensions", "name": "Form and dimensions", "description": "Shape, size, mass and the ranges these take across examples.", "findings": [ { "id": "measurable-dimensions", "name": "Measurable dimensions and their units", "description": "The quantities worth recording and the units they are recorded in.", "questions": [ { "id": "measurable-dimensions-q01", "text": "What identifies and describes the dimensions of a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "measurable-dimensions-q02", "text": "Who or what asserted this about the dimensions of a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "measurable-dimensions-q03", "text": "What may an agent decide or do once the dimensions of a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "material-and-composition", "name": "Material and composition", "description": "Materials, parts and how they are put together.", "findings": [ { "id": "parts-and-materials", "name": "Parts and materials", "description": "What a antidepressant is built from and which parts are replaceable.", "questions": [ { "id": "parts-and-materials-q01", "text": "What identifies and describes the composition of a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "parts-and-materials-q02", "text": "Who or what asserted this about the composition of a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "parts-and-materials-q03", "text": "What may an agent decide or do once the composition of a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "condition-and-integrity", "name": "Condition and integrity", "description": "Wear, damage, health and the difference between working and broken.", "findings": [ { "id": "condition-assessment", "name": "Condition, damage and health", "description": "How the condition of a antidepressant is judged and by whom.", "questions": [ { "id": "condition-assessment-q01", "text": "What identifies and describes the condition of a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "condition-assessment-q02", "text": "Who or what asserted this about the condition of a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "condition-assessment-q03", "text": "What may an agent decide or do once the condition of a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "place-and-movement", "name": "Place and movement", "description": "Where a antidepressant is, how it got there and where it may go (varies).", "rationale": "A thing that can move needs its position recorded with a time, or every later claim about it is about a place it has left.", "layers": [ { "id": "location-and-placement", "name": "Location and placement", "description": "Position, containment and the reference frame the position is given in.", "findings": [ { "id": "position-and-frame", "name": "Position, container and reference frame", "description": "Where a antidepressant is, and what that position is measured against.", "questions": [ { "id": "position-and-frame-q01", "text": "What identifies and describes the location of a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "position-and-frame-q02", "text": "Who or what asserted this about the location of a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "position-and-frame-q03", "text": "What may an agent decide or do once the location of a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "movement-and-transfer", "name": "Movement and transfer", "description": "How a antidepressant is carried, installed or relocated.", "findings": [ { "id": "movement-events", "name": "Movement events and constraints", "description": "What counts as a movement, what records it and what limits it.", "questions": [ { "id": "movement-events-q01", "text": "What identifies and describes the movement of a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "movement-events-q02", "text": "Who or what asserted this about the movement of a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "movement-events-q03", "text": "What may an agent decide or do once the movement of a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a antidepressant passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a antidepressant between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a antidepressant, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a antidepressant is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "function-and-principle", "name": "Function and operating principle", "description": "What antidepressant is for and how it achieves it.", "rationale": "Two devices with the same name can work on different principles, and the principle is what predicts failure and constrains use.", "layers": [ { "id": "intended-function", "name": "Intended function", "description": "The job it does, and the jobs it is used for anyway.", "findings": [ { "id": "function-record", "name": "Function, principle and variants", "description": "What it does, how, and which variants do it differently.", "questions": [ { "id": "function-record-q01", "text": "What function does antidepressant perform, on what operating principle, and which variants differ in that principle?", "kind": "definition" }, { "id": "function-record-q02", "text": "What use falls outside the intended function but happens in practice?", "kind": "boundary" } ] } ] }, { "id": "capacity-and-rating", "name": "Capacity and rating", "description": "The numbers that say what it can do and where it stops.", "findings": [ { "id": "ratings", "name": "Ratings and their conditions", "description": "Rated capacity, power, throughput and the conditions each assumes.", "questions": [ { "id": "ratings-q01", "text": "What ratings characterise antidepressant, in what units, and under what stated conditions?", "kind": "measurement" }, { "id": "ratings-q02", "text": "What happens beyond the rating - degradation, refusal, damage - and how is that detected?", "kind": "action" } ] } ] } ] }, { "id": "operation-and-state", "name": "Operation, controls and state", "description": "How antidepressant is operated and what state it is in right now.", "rationale": "An agent acting on a device needs its current state and the controls that change it, not just its specification.", "layers": [ { "id": "controls-and-modes", "name": "Controls and modes", "description": "What can be set, what that changes, and what is interlocked.", "findings": [ { "id": "control-surface", "name": "Control surface and interlocks", "description": "The settings available and the conditions that block them.", "questions": [ { "id": "control-surface-q01", "text": "What controls and modes does antidepressant have, and what does each change?", "kind": "definition" }, { "id": "control-surface-q02", "text": "Which actions are interlocked or forbidden in which state, and what must be true before acting?", "kind": "action" } ] } ] }, { "id": "condition-and-maintenance", "name": "Condition and maintenance", "description": "Wear, service intervals, consumables and the line between working and broken.", "findings": [ { "id": "service-record", "name": "Condition, service and consumables", "description": "What is consumed, what is serviced, and how condition is judged.", "questions": [ { "id": "service-record-q01", "text": "What consumables and service does antidepressant need, at what interval, and on whose authority?", "kind": "measurement" }, { "id": "service-record-q02", "text": "What evidence separates a unit that is working from one that is out of service?", "kind": "boundary" } ] } ] } ] }, { "id": "kind-model-unit", "name": "Kind, model and unit", "description": "Whether a claim about antidepressant is about the kind, a product line, or one physical unit.", "rationale": "This is the boundary most often got wrong for made things, and getting it wrong mixes a catalogue entry with the machine in the yard.", "layers": [ { "id": "level-of-reference", "name": "Level of reference", "description": "The three levels and what belongs at each.", "findings": [ { "id": "level-rules", "name": "What belongs to kind, model and unit", "description": "Which properties are shared by all of them and which are not.", "questions": [ { "id": "level-rules-q01", "text": "Which facts about antidepressant hold for every one of them, which for a model, and which only for one unit?", "kind": "boundary" }, { "id": "level-rules-q02", "text": "What identifies an individual unit, and what should an agent do when it has only the kind?", "kind": "action" } ] } ] }, { "id": "standards-and-conformity", "name": "Standards and conformity", "description": "The standards a working example must meet and who attests it.", "findings": [ { "id": "conformity", "name": "Standards, marks and attestation", "description": "Which standard applies, who certifies, and what the mark means.", "questions": [ { "id": "conformity-q01", "text": "Which standards govern antidepressant, issued by whom, and what does conformity actually assert?", "kind": "provenance" }, { "id": "conformity-q02", "text": "What may an agent conclude from a certification mark, and what may it not?", "kind": "boundary" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a antidepressant came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a antidepressant and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a antidepressant is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a antidepressant, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a antidepressant, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a antidepressant is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 8, "layers": 17, "findings": 19, "questions": 51 } } } }